(ATR) AptarGroup - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0383361039
Stock: Pumps, Valves, Closures, Elastomers, Digital Health
Total Rating 46
Risk 75
Buy Signal 1.08
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.60% |
| Yield on Cost 5y | 1.40% |
| Yield CAGR 5y | 5.10% |
| Payout Consistency | 100.0% |
| Payout Ratio | 32.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 38.5% |
| Relative Tail Risk | -10.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.53 |
| Alpha | -25.35 |
| Character TTM | |
|---|---|
| Beta | 0.626 |
| Beta Downside | 0.485 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.98% |
| CAGR/Max DD | 0.25 |
Description: ATR AptarGroup January 02, 2026
AptarGroup Inc. (NYSE: ATR) designs and manufactures drug-delivery and dispensing solutions across pharma, beauty, personal-care, home-care, and food-and-beverage markets. Its operations are organized into three segments-Aptar Pharma, Aptar Beauty, and Aptar Closures-and include nasal-allergy pumps, metered-dose-inhaler (MDI) valves for asthma/COPD, elastomeric injectable packaging, aerosol valves, and emerging digital-health dispensing technologies. The company serves customers globally, with sales concentrated in North America, Europe, Asia, and Latin America.
Key recent metrics: FY 2023 revenue reached approximately $2.4 billion, up ~9 % year-over-year, driven by strong demand for MDI valves and growth in the digital-health pump segment, which posted a 22 % revenue jump. The sector is being propelled by an aging global population (projected 1.5 billion people over 65 by 2030) and tightening sustainability regulations that favor reusable or recyclable dispensing components-areas where Aptar has announced new bio-based elastomer initiatives.
For a deeper, data-rich perspective on ATR’s valuation dynamics, you might find ValueRay’s analytical dashboards worth a look.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 392.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -2.25 > 1.0 |
| NWC/Revenue: 19.25% < 20% (prev 11.45%; Δ 7.80% < -1%) |
| CFO/TA 0.11 > 3% & CFO 570.0m > Net Income 392.6m |
| Net Debt (737.0m) to EBITDA (831.5m): 0.89 < 3 |
| Current Ratio: 1.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.8m) vs 12m ago -3.13% < -2% |
| Gross Margin: 29.58% > 18% (prev 0.38%; Δ 2920 % > 0.5%) |
| Asset Turnover: 78.00% > 50% (prev 80.84%; Δ -2.84% > 0%) |
| Interest Coverage Ratio: 10.32 > 6 (EBITDA TTM 831.5m / Interest Expense TTM 52.7m) |
Altman Z'' 3.29
| A: 0.14 (Total Current Assets 1.89b - Total Current Liabilities 1.17b) / Total Assets 5.25b |
| B: 0.49 (Retained Earnings 2.60b / Total Assets 5.25b) |
| C: 0.11 (EBIT TTM 544.1m / Avg Total Assets 4.84b) |
| D: 0.01 (Book Value of Equity 26.2m / Total Liabilities 2.54b) |
| Altman-Z'' Score: 3.29 = A |
Beneish M -2.65
| DSRI: 1.16 (Receivables 803.8m/658.1m, Revenue 3.78b/3.58b) |
| GMI: 1.28 (GM 29.58% / 37.83%) |
| AQI: 0.98 (AQ_t 0.32 / AQ_t-1 0.33) |
| SGI: 1.05 (Revenue 3.78b / 3.58b) |
| TATA: -0.03 (NI 392.6m - CFO 570.0m) / TA 5.25b) |
| Beneish M-Score: -2.65 (Cap -4..+1) = A |
What is the price of ATR shares?
As of February 09, 2026, the stock is trading at USD 134.31 with a total of 884,680 shares traded.
Over the past week, the price has changed by +8.01%, over one month by +10.12%, over three months by +15.85% and over the past year by -5.00%.
Over the past week, the price has changed by +8.01%, over one month by +10.12%, over three months by +15.85% and over the past year by -5.00%.
Is ATR a buy, sell or hold?
AptarGroup has received a consensus analysts rating of 4.29.
Therefore, it is recommended to buy ATR.
- StrongBuy: 4
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ATR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 159.9 | 19% |
| Analysts Target Price | 159.9 | 19% |
| ValueRay Target Price | 140 | 4.2% |
ATR Fundamental Data Overview February 08, 2026
P/E Trailing = 22.7644
P/E Forward = 24.57
P/S = 2.4159
P/B = 2.9373
P/EG = 4.8234
Revenue TTM = 3.78b USD
EBIT TTM = 544.1m USD
EBITDA TTM = 831.5m USD
Long Term Debt = 546.0m USD (from longTermDebt, two quarters ago)
Short Term Debt = 286.8m USD (from shortTermDebt, two quarters ago)
Debt = 1.14b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 737.0m USD (from netDebt column, last quarter)
Enterprise Value = 9.58b USD (8.85b + Debt 1.14b - CCE 409.5m)
Interest Coverage Ratio = 10.32 (Ebit TTM 544.1m / Interest Expense TTM 52.7m)
EV/FCF = 32.41x (Enterprise Value 9.58b / FCF TTM 295.6m)
FCF Yield = 3.09% (FCF TTM 295.6m / Enterprise Value 9.58b)
FCF Margin = 7.83% (FCF TTM 295.6m / Revenue TTM 3.78b)
Net Margin = 10.40% (Net Income TTM 392.6m / Revenue TTM 3.78b)
Gross Margin = 29.58% ((Revenue TTM 3.78b - Cost of Revenue TTM 2.66b) / Revenue TTM)
Gross Margin QoQ = 20.36% (prev 29.95%)
Tobins Q-Ratio = 1.82 (Enterprise Value 9.58b / Total Assets 5.25b)
Interest Expense / Debt = 1.49% (Interest Expense 17.0m / Debt 1.14b)
Taxrate = 18.85% (17.3m / 91.5m)
NOPAT = 441.5m (EBIT 544.1m * (1 - 18.85%))
Current Ratio = 1.62 (Total Current Assets 1.89b / Total Current Liabilities 1.17b)
Debt / Equity = 43.42 (Debt 1.14b / totalStockholderEquity, last quarter 26.2m)
Debt / EBITDA = 0.89 (Net Debt 737.0m / EBITDA 831.5m)
Debt / FCF = 2.49 (Net Debt 737.0m / FCF TTM 295.6m)
Total Stockholder Equity = 2.02b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.11% (Net Income 392.6m / Total Assets 5.25b)
RoE = 19.48% (Net Income TTM 392.6m / Total Stockholder Equity 2.02b)
RoCE = 21.24% (EBIT 544.1m / Capital Employed (Equity 2.02b + L.T.Debt 546.0m))
RoIC = 11.72% (NOPAT 441.5m / Invested Capital 3.77b)
WACC = 7.42% (E(8.85b)/V(9.99b) * Re(8.22%) + D(1.14b)/V(9.99b) * Rd(1.49%) * (1-Tc(0.19)))
Discount Rate = 8.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.00%
[DCF Debug] Terminal Value 83.17% ; FCFF base≈317.0m ; Y1≈391.1m ; Y5≈666.0m
Fair Price DCF = 183.0 (EV 12.75b - Net Debt 737.0m = Equity 12.01b / Shares 65.6m; r=7.42% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 81.34 | EPS CAGR: 7.29% | SUE: 0.26 | # QB: 0
Revenue Correlation: 77.53 | Revenue CAGR: 3.54% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.15 | Chg30d=-0.052 | Revisions Net=-4 | Analysts=6
EPS current Year (2026-12-31): EPS=5.56 | Chg30d=-0.009 | Revisions Net=-2 | Growth EPS=-3.1% | Growth Revenue=+2.6%
EPS next Year (2027-12-31): EPS=6.44 | Chg30d=+0.132 | Revisions Net=-3 | Growth EPS=+15.9% | Growth Revenue=+5.2%
P/E Forward = 24.57
P/S = 2.4159
P/B = 2.9373
P/EG = 4.8234
Revenue TTM = 3.78b USD
EBIT TTM = 544.1m USD
EBITDA TTM = 831.5m USD
Long Term Debt = 546.0m USD (from longTermDebt, two quarters ago)
Short Term Debt = 286.8m USD (from shortTermDebt, two quarters ago)
Debt = 1.14b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 737.0m USD (from netDebt column, last quarter)
Enterprise Value = 9.58b USD (8.85b + Debt 1.14b - CCE 409.5m)
Interest Coverage Ratio = 10.32 (Ebit TTM 544.1m / Interest Expense TTM 52.7m)
EV/FCF = 32.41x (Enterprise Value 9.58b / FCF TTM 295.6m)
FCF Yield = 3.09% (FCF TTM 295.6m / Enterprise Value 9.58b)
FCF Margin = 7.83% (FCF TTM 295.6m / Revenue TTM 3.78b)
Net Margin = 10.40% (Net Income TTM 392.6m / Revenue TTM 3.78b)
Gross Margin = 29.58% ((Revenue TTM 3.78b - Cost of Revenue TTM 2.66b) / Revenue TTM)
Gross Margin QoQ = 20.36% (prev 29.95%)
Tobins Q-Ratio = 1.82 (Enterprise Value 9.58b / Total Assets 5.25b)
Interest Expense / Debt = 1.49% (Interest Expense 17.0m / Debt 1.14b)
Taxrate = 18.85% (17.3m / 91.5m)
NOPAT = 441.5m (EBIT 544.1m * (1 - 18.85%))
Current Ratio = 1.62 (Total Current Assets 1.89b / Total Current Liabilities 1.17b)
Debt / Equity = 43.42 (Debt 1.14b / totalStockholderEquity, last quarter 26.2m)
Debt / EBITDA = 0.89 (Net Debt 737.0m / EBITDA 831.5m)
Debt / FCF = 2.49 (Net Debt 737.0m / FCF TTM 295.6m)
Total Stockholder Equity = 2.02b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.11% (Net Income 392.6m / Total Assets 5.25b)
RoE = 19.48% (Net Income TTM 392.6m / Total Stockholder Equity 2.02b)
RoCE = 21.24% (EBIT 544.1m / Capital Employed (Equity 2.02b + L.T.Debt 546.0m))
RoIC = 11.72% (NOPAT 441.5m / Invested Capital 3.77b)
WACC = 7.42% (E(8.85b)/V(9.99b) * Re(8.22%) + D(1.14b)/V(9.99b) * Rd(1.49%) * (1-Tc(0.19)))
Discount Rate = 8.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.00%
[DCF Debug] Terminal Value 83.17% ; FCFF base≈317.0m ; Y1≈391.1m ; Y5≈666.0m
Fair Price DCF = 183.0 (EV 12.75b - Net Debt 737.0m = Equity 12.01b / Shares 65.6m; r=7.42% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 81.34 | EPS CAGR: 7.29% | SUE: 0.26 | # QB: 0
Revenue Correlation: 77.53 | Revenue CAGR: 3.54% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.15 | Chg30d=-0.052 | Revisions Net=-4 | Analysts=6
EPS current Year (2026-12-31): EPS=5.56 | Chg30d=-0.009 | Revisions Net=-2 | Growth EPS=-3.1% | Growth Revenue=+2.6%
EPS next Year (2027-12-31): EPS=6.44 | Chg30d=+0.132 | Revisions Net=-3 | Growth EPS=+15.9% | Growth Revenue=+5.2%